A current review article addressed the management of gout patients with chronic kidney disease (CKD).  This full read review addresses the epidemiology, challenges, treatment decisions and outcomes. 

In RA, the goal is to control or arrest inflammation such that articular and bony damage is halted. While we have many effective therapies, it is not clear that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis outcomes in RA. A current real-world study showed that 1 year of b/tsDMARDs use did not arrest osteoporosis progression.

The American College of Rheumatology (ACR) recently joined with 16 other healthcare organizations to submit comments to the U.S. Department of Education (ED) in response to its proposal to exclude nurses, physician assistants, physical therapists, and social workers, among other crucial healthcare professionals, from the definition of “professional degree” for federal student loan purposes.

A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.

About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.